Overgrowth

Abstract

Get full access to this article

View all access options for this article.

References

1. Sotos JF , Romshe CA . Giantism and Acromegaly. In: Gardner L , ed. Endocrine and Genetic Diseases of Childhood. Philadelphia: WB Saunders Co; 1975.

2. Daughaday WH . Pituitary gigantism. Endocrinol Metab Clin North Am. 1992; 21: 633-647.

3. Blumberg DL , Sclar CA , David R , et al. Acromegaly in an infant. Pediatrics. 1989;83: 998-1002.

4. Vogl TJ , Nerlich A , Dresel SH , Bergman C . CT of the “Tegernsee Giant”: juvenile gigantism and polyostotic fibrous dysplasia. J Computer Assist Tomogr. 1994; 18: 319-322.

5. Gelber SJ , Heffez DS , Donohoue PA . Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr. 1992; 120: 931-934.

6. Lu PW , Silink M , Johnston I , et al. Pituitary gigantism. Arch Dis Child. 1992; 67: 1039-1041.

7. Iwatani N , Kodama M , Seto H . A child with pituitary gigantism and precocious adrenarche: does GH and/or PRL advance the onset of adrenarche? EndocrinolJpn. 1992;39:251-257.

8. Matsuura H , Kitazawa Y , Tanaka M , Morooka K . Pituitary adenoma and unexpected sudden infant death: a case report. Med Pediatr Oncol. 1994; 22: 283-286.

9. Fazekas I , Pasztor E , Slowik F , et al. Pathological and experimental investigations in a case of gigantism. Acta NeuropathoL. 1993; 85: 167-174.

10.

10. Zimmerman D , Young WF Jr , Ebersold MJ , et al. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab. 1993;76: 216-222.

11.

11. Moran A , Asa SL , Kovacs K , et al. Gigantism due to pituitary mammosomatotroph hyperplasia. New Engl J Med. 1990; 323: 322-327.

12.

12. Araki Y , Sakai N , Andoh T , et al. Central neurocytoma presenting with gigantism: case report. Surg Neurol. 1992; 38: 141-145.

13.

13. Cuttler L , Jackson JA , Saeed us-Zafar M , Levitsky LL . Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab. 1989; 68: 1148-1154.

14.

14. von Werder K , Losa M , Stalla GK , et al. Long-term treatment of a metastasizing GRFoma with a somatostatin analogue (SMS 201-995) in a girl with gigantism. ScandJ Gastroenterol. 1986; 119 (Suppl 21):238-238.

15.

15. Espiner EA , Carter TAH , Abbott GD , Wrightson P . Pituitary gigantism in a 31 month old girl: endocrine studies and successful response to hypophysectomy. J Endocrinol Invest. 1981;4: 445-450.

16.

16. Alexander L , Appleton D , Hall R , et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol. 1980; 12: 71-79.

17.

17. Hayles AB . Gigantism. Pediatr Ann. 1980; 9: 163-169.

18.

18. Joishy SK , Morrow LB . McCune-Al-bright syndrome associated with a functioning pituitary chromophobe adenoma.JPediatr. 1976;89:73-75.

19.

19. Lightner ES , Penny R , Frasier SD . Pituitary adenoma in McCune-Albright syndrome: follow-up information. JPediatr. 1976;89:159-159.

20.

20. Nakagawa H , Nagasaka A , Sugiura T , et al. Gigantism associated with McCune-Albright's syndrome. Horm Metab Res. 1985; 17: 522-527.

21.

21. Kovacs K , Horvath E , Thorner MO , Rogol AD . Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis Virchows Archiv (Patholog Anat Histopathol). 1984; 403: 77-84.

22.

22. Asa SL , Scheithouer BW , Bilbao JM , et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab. 1984; 58: 796-803.

23.

23. Bevan JS , Asa SL , Rossi ML , et al. Intrasellar gangliocytoma containing gastrin and growth hormone-releasing hormone associated with a growth hormone-secreting pituitary adenoma. Clin Endocrinol. 1989; 30: 213-224.

24.

24. Gilsanz Peral A , Gomez Balaguer M , Alberola Carbonell C , et al. Evidencia de la produccion por un tumor carcinoide pulmonar del factor liberador de la hormona del crecimiento causante de acromegalia. Med Clinica. 1987; 89: 789-792.

25.

25. Glikson M , Gil-Ad I , Galum E , et al. Acromegaly due to ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumour. Dynamic hormonal responses to various stimuli. Acta Endocrinol. 1991; 124: 366-371.

26.

26. Faglia G , Arosio M , Bazzoni N . Ectopic acromegaly. Endocrinol Metab Clin North Am. 1992; 21: 575-595.

27.

27. Melmed S . Etiology of pituitary acromegaly. Endocrinol Metab Clin North Am. 1992; 21: 539-552.

28.

28. Thorner MO , Vance ML , Horvath E , Kovacs K . The anterior pituitary. In: Wilson JD , Foster DW , eds. Williams' Textbook of Endocrinology 8th ed. Philadelphia: WB Saunders Co; 1992.

29.

29. Vallar L , Spada A , Giannattasio G . Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987; 330: 566-568.

30.

30. Landis CA , Masters SB , Spada A , et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. Nature. 1989; 340: 692-696.

31.

31. Weinstein LS , Shenker A , Gejman PV , et al. Activating mutations of the stimulatory G protein in the McCune-Albright Syndrome. New Engl J Med. 1991;325:1688-1688.

32.

32. Bystrom C , Larsson C , Blomberg C , et al. Localization of the MEN1 gene to a small region within chromosome 1 1q1 3 by deletion mapping in tumors. Proc Nat Acad Sci USA. 1990; 87: 1968-1972.

33.

33. Asa SL , Kovacs K Pituitary pathology in acromegaly. Endocrinol Metab Clin North Am. 1992;21:553-574.

34.

34. Nelson C , Albert VR , Elsholtz HP , et al. Activation of cell-specific expression of rat growth hormone and prolactin genes by a common transcription factor. Science. 1988; 239: 1400-1405.

35.

35. Melmed S . Acromegaly. NEnglJMed. 1990; 322: 966-977.

36.

36. Hartman ML . The adverse systemic effects of growth hormone in acromegaly. Growth GenetHorm. 1990; 6: 1-5.

37.

37. Bates AS , Van't Hoff W , Jones JM , Clayton RN . An audit of outcome of treatment in acromegaly. QJ Med. 1993; 86: 293-299.

38.

38. Palmiter RD , Brinster RL , Hammer RE , et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature. 1982;300: 611-615.

39.

39. Hammer RE , Brinster RL , Rosenfeld MG , et al. Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature. 1985; 315: 413-416.

40.

40. Quaife CJ , Mathews LS , Pinkert CA , et al. Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology. 1989; 124:4048-4048.

41.

41. Chang-DeMoranville BM , Jackson IMD . Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am. 1992; 21: 649-668.

42.

42. Hindmarsh PC , Pringle PJ , Brook CG . The 24-hour growth hormone secretion in a boy with giantism. Acta Endocrinol. 1988; 117: 403-408.

43.

43. Hartman ML , Veldhuis JD , Vance ML , et al. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab. 1990; 70: 1375-1384.

44.

44. Clemmons DR , Van Wyk JJ , Ridgway EC , Kliman B . Evaluation of acromegaly by radioimmunoassay of somatomedin-C. NEnglJ Med. 1979;301: 1138-1142.

45.

45. Melmed S , Ziel FH , Braunstein GD , et al. Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor. J Clin Endocrinol Metab. 1988; 67: 395-399.

46.

46. Moller DE , Moses AC , Jones K . Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. JEndocrinol Metab. 1989;68:499-499.

47.

47. Fahlbusch R , Honegger J , Buchfelder M . Surgical management of acromegaly. Endocrinol Metab Clin North Am. 1992; 21: 669-692.

48.

48. Ross DA , Wilson CB . Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. JNeurosurg. 1988; 68: 854-867.

49.

49. Eastman RC , Gorden P , Glatstein E , Roth J . Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 1992; 21: 693-712.

50.

50. Sheline GE , Wara WM , Smith V . Therapeutic irradiation and brain injury. IntJRadiat Oncol, Biol, Phys. 1980;6: 1215-1228.

51.

51. Soni SS , Marten GW , Pitner SE , et al. Effects of central-nervous-system irradiation on neuropsychologic functioning of children with acute lymphocytic leukemia. NEnglJMed. 1975; 293: 113-118.

52.

52. Shalet SM , Beardwell CG , Morris-Jones P , et al. Growth hormone deficiency in children with brain tumors. Cancer. 1976;37(Suppl 2):1144-1148.

53.

53. Eiser C . Intellectual abilities among survivors of childhood leukaemia as a function of CNS irradiation. Arch Dis Child. 1978; 53: 391-395.

54.

54. Kliman B , Kjellberg RN , Swisher B , et al. Proton beam therapy of acromegaly: a 20-year experience. In: Black PM , Zervas NT , Ridgway EC , et al, eds. Secretory Tumors of the Pituitary Gland. Progress in Endocrine Research and Therapy, vol 1. New York: Raven; 1984:191-211.

55.

55. Lamberts SW . The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988; 9: 417-436.

56.

56. Lamberts SWJ , Reubi JC , Krenning EP . Somatostatin analogs in the treatment of acromegaly. Endocrinol Metab Clin North Am. 1992; 21: 737-752.

57.

57. Vance ML , Harris AG . Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med. 1991;151: 1573-1578.

58.

58. Heron I , Thomas F , Dero M , et al. Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog. Presse Med (Paris). 1993; 22: 526-531.

59.

59. Melmed S , Ho K , Klibanski A , et al. Clinical Review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 1995;80:3395-3395.

60.

60. Morangi I , De Boisvilliers F , Chanson P , et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 1994; 79: 145-151.

61.

61. Marek J , Hana V , Krsek M , et al. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol. 1994; 131: 20-26.

62.

62. Jaffe CA , Barkan AL . Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992; 21: 713-736.

63.

63. Kocijancic A , Prezelj J , Vrhovec I , Lan-cranjan I . Parlodel LAR in the treatment of macroprolactinomas. Acta EndocrinoL 1990; 122: 272-276.

64.

64. Jaffe CA , Friberg RD , Barkan AL . Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest. 1993; 92: 695-701.